Gossamer Bio

What Gossamer Bio does

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products, with its core asset seralutinib—an investigational, inhaled, small-molecule kinase inhibitor targeting PDGFRα/β, CSF1R, and c-Kit—delivered via dry powder inhaler (DPI) directly to the lungs for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's differentiated drug-device combination approach positions seralutinib as potentially the only late-stage clinical asset designed to reverse pathological vascular remodeling in PAH, rather than acting purely as a vasodilator. Gossamer Bio operates through a global collaboration with Chiesi Farmaceutici S.p.A. for ex-U.S. commercialization while leading U.S. commercialization independently. The company faces significant clinical and financial headwinds following the February 2026 failure of its Phase 3 PROSERA trial, which triggered a subsequent 48-50% workforce reduction, an 80% stock decline, and a debt restructuring that reduced outstanding convertible notes from $200M to approximately $72M.

Name

Gossamer Bio

Legal name

Gossamer Bio, Inc.

Website

https://gossamerbio.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Clinical-stage biopharmaceutical company developing seralutinib, an inhaled PDGFRα/β, CSF1R, c-Kit kinase inhibitor, delivered via dry powder inhaler for treatment of pulmonary arterial hypertension and PH-ILD, facing major clinical and financial setbacks following Phase 3 PROSERA trial failure.

Ownership category

akta.pro rank

Product category

Pulmonary Hypertension Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)

Keywords

• Pulmonary hypertension therapeutics
• Inhaled kinase inhibitors
• Rare disease biopharmaceuticals
• Dry powder inhaler drugs
• Clinical stage drug development

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Collaboration revenue from Chiesi partnership: Q1 2026 revenue of $17.0 million, rising 71% year-over-year, primarily driven by collaboration revenue from the partnership with Chiesi Group including $9.3 million in cost reimbursement. Revenue stream tied to development cost-sharing under the May 2024 global collaboration and license agreement.
2. Future milestone payments from Chiesi: Gossamer Bio eligible to receive up to $146 million in regulatory milestones and $180 million in sales milestones under its May 2024 collaboration with Chiesi Farmaceutici S.p.A. for seralutinib development and commercialization.
3. Future US product sales (PAH and PH-ILD): Future US commercial revenue from seralutinib sales, with Gossamer Bio leading US commercialization and booking sales. Companies will evenly share commercial profits and losses in the US for both PAH and PH-ILD indications.
4. Future ex-US royalty stream from Chiesi: Chiesi will have exclusive rights to commercialize seralutinib outside the US and will pay Gossamer Bio an escalating mid-to-high teens royalty on net sales in ex-US markets.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Gossamer Bio is developing seralutinib, an investigational, inhaled small-molecule kinase inhibitor of PDGFRα/β, CSF1R, and c-KIT, delivered via a proprietary dry powder inhaler (DPI) drug-device combination. The product is being investigated for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), with the goal of reversing pathological vascular remodeling through anti-inflammation, anti-proliferation, and anti-fibrosis mechanisms rather than acting as a vasodilator.

Product overview

Gossamer Bio is a clinical-stage biopharmaceutical company with a single-asset focused portfolio built around its investigational drug product seralutinib. The company's offering is not a multi-product platform but rather a focused clinical-stage pipeline anchored on one inhaled small-molecule inhibitor (PDGFRα/β, CSF1R, c-KIT) targeting pulmonary hypertension. The named products and clinical programs within this portfolio are: seralutinib (the core investigational drug product, delivered via dry powder inhaler); the Phase 3 PROSERA Study in pulmonary arterial hypertension (PAH); the Phase 3 SERANATA Study in pulmonary hypertension associated with interstitial lung disease (PH-ILD); the completed Phase 2 TORREY Study in PAH; and the open-label extension studies (PROSERA-EXT and PAH OLE) providing long-term safety and efficacy follow-up. These products/programs are all variations or stages of development of the same underlying asset (seralutinib) and together constitute the entirety of Gossamer Bio's product portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• Seralutinib: Investigational inhaled small molecule inhibitor of PDGFRα/β, CSF1R, and c-KIT, delivered via dry powder inhaler for PAH and PH-ILD. Previously known as GB002.

Products and services

• Seralutinib Seralutinib is an investigational, inhaled, small-molecule inhibitor of platelet-derived growth factor receptor (PDGFRα/β), colony-stimulating factor 1 receptor (CSF1R), and mast/stem cell growth factor receptor kit (c-KIT), intentionally designed to target mechanisms underlying pulmonary hypertension and delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Quantifiable outcome

• Phase 3 PROSERA trial placebo-adjusted improvement of +13.3 meters in Six-Minute Walk Distance at Week 24 (p=0.0320)
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered flagship - core strategic partnership defining gossamer bio's global commercialization path for seralutinib, minor - patient advocacy partnership and minor - medical research partnership.

• Chiesi Farmaceutici S.p.A.flagship - core strategic partnership defining gossamer bio's global commercialization path for seralutinibStrategic or Co-development Partner · 1 May 2024In May 2024, Gossamer Bio and Chiesi Farmaceutici entered into a global collaboration and license agreement to develop and commercialize seralutinib. Under the agreement: Gossamer leads global development of seralutinib in PAH and PH-ILD; companies evenly split development costs (except PROSERA Study which Gossamer funds alone); in US, companies evenly share commercial profits and losses with Gossamer leading commercialization and booking sales; Chiesi leads US commercialization in additional indications; Chiesi has exclusive ex-US commercialization rights paying escalating mid-to-high teens royalty on net sales; Gossamer eligible for up to $146M in regulatory milestones and $180M in sales milestones.
• PHA Europeminor - patient advocacy partnershipGTM or Marketing PartnerPatient advocacy organization supporting clinical trial awareness and education for the PAH community in Europe.
• Pulmonary Hypertension Association (PHA)minor - patient advocacy partnershipGTM or Marketing PartnerPatient advocacy organization supporting clinical trial awareness, patient education, and disease awareness for the PAH community in the US.
• Team PHenomenal Hopeminor - patient advocacy partnershipGTM or Marketing PartnerPatient advocacy organization supporting clinical trial participation, patient education, and disease awareness for the PAH/PH-ILD community.
• phaware globalminor - patient advocacy partnershipGTM or Marketing PartnerPatient advocacy organization supporting global awareness and education for pulmonary hypertension, featured in clinical trial awareness materials.
• Pulmonary Vascular Research Institute (PVRI)minor - medical research partnershipGTM or Marketing PartnerMedical research organization supporting scientific conferences and education in pulmonary vascular disease.

Scale indicators15 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• United Therapeutics Corporation: United Therapeutics is a direct competitor in PAH with Tyvaso DPI and Remodulin (inhaled and infused treprostinil), and is the current standard-of-care inhaled therapy in PAH — directly comparable to Gossamer Bio's seralutinib DPI product. Gossamer SVP Rob Roscigno is a former principal developer of Remodulin at United Therapeutics.
• Liquidia Corporation: Liquidia is a direct PAH competitor with YUTREPIA (inhaled treprostinil) and is a near-term rival in the inhaled PAH space; Gossamer's SVP Rob Roscigno previously led the LIQ861 program at Liquidia, making the overlap on assets, modality (inhaled DPI), and talent highly comparable.
• Acceleron Pharma (Merck): Acceleron's WINREVAIR (sotatercept), now marketed by Merck following an $11B+ acquisition, is a recently approved PAH therapy targeting a distinct mechanism, and is a direct competitive threat to seralutinib in the same patient population; Gossamer director John Quisel led the sotatercept re-acquisition effort at Acceleron.

Emerging players

• Aerovate Therapeutics: Aerovate is an emerging PAH-focused company developing inhaled imatinib for pulmonary arterial hypertension, sharing the same targeted-DPI-for-PAH model as seralutinib and competing for similar specialist physician adoption, albeit with a kinase-inhibitor mechanism aimed at a different pathway.
• Insmed Incorporated: Insmed is a commercial-stage inhaled therapeutics company with ARIKAYCE for nontuberculous mycobacterial lung disease, sharing the rare-disease inhaled-pulmonary delivery model with seralutinib and demonstrating the commercial viability of inhaled specialty lung disease drugs.
• MannKind Corporation: MannKind is a specialty pulmonary and endocrine company built around dry powder inhaler drug-device platforms (Afrezza, Tyvaso DPI collaboration with United Therapeutics), and is a technology-platform comparable to seralutinib's DPI delivery approach.

Broad incumbents

• Actelion / Janssen Pharmaceuticals (J&J): Actelion (acquired by J&J for $30B) is the historical market leader in PAH with OPSUMIT, UPTRAVI, and Tracleer; several Gossamer executives (Bob Smith, Jeanine Anthony) are former Actelion PAH launch leaders, making J&J the dominant incumbent comparable for understanding seralutinib's competitive context.
• Bayer Pharmaceuticals (Adempas / riociguat): Bayer markets Adempas (riociguat) in PAH/PH-ILD, making it a broad incumbent in the same indication space as seralutinib and a reference for specialty distribution and PH-accredited center engagement.

Others

• Disc Medicine: Disc Medicine is a clinical-stage hematology and rare-disease company whose CEO (John Quisel) is a Gossamer board member, providing a comparable reference point for a small-cap rare-disease biopharma pursuing an NDA path with limited commercial infrastructure.
• Pulmokine Inc. Pulmokine is a private company with a secondary-market economic interest in seralutinib (acquired by XOMA Royalty for $20M); it serves as an adjacent ecosystem reference to Gossamer Bio's seralutinib program and a small-cap comparable in the inhaled PAH development space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gossamer-bio
• Xx.com/gossamerbio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors27 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gossamer Bio